Company:                          Addex Pharmaceuticals
Ticker Symbol & Exchange:         ADXN
Media Contact:                    Chris Maggos
Phone:                            41 22 884 15 11
E-mail:                           chris.maggos@addexpharma.com
Web:                               www.addexpharma.com
Addex Pharmaceuticals discovers and develops allosteric modulators
for human health. Allosteric modulators are a different kind of
orally available small molecule therapeutic agent, which we
believe will offer patients better results than classical drugs.
The lead product in our pipeline, ADX10059, has achieved clinical
proof of concept and is in Phase IIb testing for the treatment of
GERD (e.g. heartburn) and, separately, migraine headache. ADX10059
is a first-in-class mGluR5 inhibitor, a therapeutic strategy that
also is being pursued for multiple indications by large pharma
competitors.
ADX10059 is not yet partnered but we have established drug
development deals with Merck & Co., Inc. (2 deals: schizophrenia &
Parkinson's) and Ortho McNeil Pharmaceuticals, a J&J company
(anxiety/schizophrenia). Roche Ventures and SR One
(GlaxoSmithKline's VC investing unit) have invested in Addex.
Company:                          Allon Therapeutics Inc.
Ticker Symbol & Exchange:         TSX:NPC
Media Contact:                    Aaron Keay, Director, Investor Relations
Phone:                            604-742-2540
E-mail:                           akeay@allontherapeutics.com
Web:                               www.allontherapeuticsc.com
Allon Therapeutics Inc. is a clinical-stage biotechnology company
developing treatments for major neurodegenerative conditions.
Allon's drug AL-108 (davunetide) has demonstrated human efficacy in
amnestic mild cognitive impairment, a precursor to Alzheimer's
disease. Allon has Phase II human efficacy programs pursuing large
underserved markets: Alzheimer's disease, frontotemporal dementia,
and schizophrenia-related cognitive impairment.
Company:                          Almac Group
Stand:                            10
Media Contact:                    Carl Whyte (Stakeholder Communicati)
Phone:                            44(0)28 3833 2200
E-mail:                           info@almacgroup.com
Web:                               www.almacgroup.com
Almac's integrated development services extend from research to
commercialisation of product. Our extensive facilities in Europe
and North America offer the following:
-Route design & synthesis of APIs (including potent, peptide and
chiral compounds);
-Synthesis and formulation of labelled compounds (pre-clinical and
clinical);
-Formulation development of tablets and capsules;
-Gene expression profiling & bioinformatics;
-Manufacturing/blinding, packaging, randomised labelling and
distribution of clinical supplies;
-Clinical trial technology solutions based on IVRS/Web/EDC;
-Commercial scale manufacture and distribution;
-Comprehensive analytical service;
-EU import testing and QP release for clinical and commercial
product.
Company:                          AmberCRO, ltd
Media Contact:                    Julija Gabrusenoka
Phone:                            37129340168
E-mail:                           gabrusenokaj@amber-cro.com
Web:                               www.amber-cro.com
AmberCRO is a private CRO company providing Contract Research
Organization services in Baltic Countries.
Started from feasibility to Close out Visits including additional
services:
Independent Audit services
Study Design, Protocol Development, Case report Form, Design and
Preparation.
Selection process. Site and Investigator selection.
Regulatory Consultation. Preparation and submission of Regulatory
documents (clinical trial application/ Notification).
Organize Investigator meeting, qualify and train Investigators
ICH/GCP training
Site Management and Monitoring Based on SOP's and study specific
procedures.
AmberCRO is providing services for reasonable price with high
quality.
AmberCRO has established its own EDC system with High data
security, elastic database structure, easy navigation, simple data
verification system, comprehensive report system.
Company:                           FGK Clinical Research GmbH
Stand:                             18
Media Contact:                     Dr. Edgar J. Fenzl
Phone:                             49 - 89 - 893119-0
E-mail:                            edgar.fenzl@fgk-cro.de
Web:                                www.fgk-cro.de
FGK Clinical Research GmbH is a full service contract research
organization offering a complete range of clinical development and
consulting services to pharmaceutical, biotechnology and medical
device companies.
With more than 50 highly skilled and experienced people, FGK
operates out of Munich on local and global projects, covering
clinical studies from phases II to IV. FGK has extensive experience
in all major therapeutic areas and clinical research fields, which
allows it to effectively design, manage and analyze your development
programs and clinical trials.
Company:                           Hospira One 2 One
Stand:                             4
Ticker Symbol & Exchange:          HSP
Phone:                             44 (0) 1926 835 554
E-mail:                            one2one@hospira.com
Web:                                http://one2one.hospira.com
Hospira is a global specialty pharmaceutical and medication delivery
company. The company's One 2 One(R) business is a world leader in the
custom development and manufacture of parenteral products packaged
in vials, prefilled syringes, cartridges, flexible containers and
ampules.
One 2 One(R) offers development and manufacturing services at its
worldwide facilities located in North America, Europe and Australia.
Company:                           Hybrigenics
Ticker Symbol & Exchange:          ALHYG (NYSE-Euronext)
Phone:                             (33) 1 58 10 38 00
E-mail:                            contact@hybrigenics.com
Web:                                www.hybrigenics.com
Hybrigenics is a public bio-pharmaceutical company focusing its R&D
programs on innovative targets and therapeutics against cancer. Its
most advanced development program is based on inecalcitol, a vitamin
D analogue, for prostate cancer in combination with reference
treatments, for improved efficacy and better tolerance. Hybrigenics'
research program explores the role of Ubiquitin-Specific Proteases
(USPs) in the degradation of proteins involved in cancer
(oncoproteins), and the use of proprietary USP inhibitors against
various cancer types.
Hybrigenics also commercializes expert protein interaction services
dedicated to identify, validate and inhibit protein interactions for
academic and industrial researchers from all life sciences. Its
flagship technology is a unique ISO 9001-certified Yeast-Two Hybrid
(Y2H) high throughput screening platform, backed by bioinformatic
tools.
Company:                           InNexus Biotechnology Inc.
Ticker Symbol & Exchange:          IXS.V: Toronto Stock Exchange
Media Contact:                     Jeff Morhet, Chairman & CEO
Phone:                             480-862-7500
E-mail:                            jmorhet@ixsbio.com
Web:                                www.ixsbio.com
InNexus is a drug development company commercializing the next
generation of monoclonal antibodies based on its DXL(TM) technology,
which improves the potency of existing antibody products while
opening new markets and disease applications.
In a short period of time, InNexus has assembled facilities,
resources, a stellar Scientific Advisory Board, staff and milestones
yielding multiple pre-clinical candidates targeting cancer and other
commercial opportunities. InNexus has launched into pre-clinical
development its first four products, DXL625 (CD20) for non-Hodgkin's
lymphoma, DXL702 (HER-2/neu) for breast cancer, DXL1218 for
colorectal cancer and DXL1215 for endometriosis. InNexus has
numerous products and platform opportunities for antibodies.
Company:                           PEPperPRINT GmbH
Media Contact:                     Dr. Volker Stadler
Phone:                             49-6221-424744
E-mail:                            info@pepperprint.com
Web:                                www.pepperprint.com
By means of laser printing, PEPperPRINT produces high density
peptide and peptidomimetic arrays on conventional glass slides.
For the first time, tens of thousands of individual peptides are
available at moderate costs. PEPperPRINT markets customized
peptide arrays on demand for proteome research (antibody
profiling, epitope mapping, screening for enzyme substrates...).
Additionally, on a fee-for-service basis, PEPperPRINT provides
truly large scale peptide and peptidomimetic libraries for
biomarker discovery and drug development. PEPperPRINT adds speed
and throughput on your experiment.
Company:                          Resverlogix Corp.
Ticker Symbol & Exchange:         TSX:RVX
Media Contact:                    Theresa Kennedy
Phone:                            1.604.538.7072
E-mail:                           Theresa@Resverlogix.com
Web:                               www.resverlogix.com
Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets
with significant unmet needs. The NexVas(TM) PR (plaque regression)
program is the Company's primary focus which is to develop novel
small molecules that enhance ApoA-I. These vital therapies address
the grievous burden of atherosclerosis and other important diseases
such as acute coronary syndrome, diabetes, Alzheimer's disease,
Peripheral Artery Disease and other vascular disorders. Resverlogix
Corp. trades on the Toronto Stock Exchange  (CA:RVX:
news
,
chart
,
profile
)
. For further
information please visit  www.resverlogix.com
Company:                          ViroStatics, srl
Media Contact:                    Michael Stevens
Phone:                            1 609 213-5287
E-mail:                           m.stevens@virostatics.com
Web:                              virostatics.com
Dr. Franco Lori, Chief Executive Officer of Virostatics, will
present a Company overview during BIO-Europe Spring 2009 at 09:30
AM on Wednesday, 18 March, 2009. Dr. Lori will update recent
Company advancements in drug discovery and development in the
areas of HIV/AIDS and cancer as well as the potential for the
Company's proprietary biomarker assays. Dr. Lori will review how
Anti-Viral Hyper-Activation Limiting Therapies (AV-HALT) represent
a new family of antivirals designed to not only suppress viruses
but also to preserve the immune system from chronic damage. Dr.
Lori will also discuss in-licensing and partnering opportunities
in HIV/AIDS and cancer.